We report the case of a 49-year-old male with clinical and histological findings consistent with hypertrophic lupus erythematosus (HLE). HLE must be clinically and histologically differentiated from keratoacanthoma, hypertrophic lichen planus, squamous cell carcinoma and plaque type psoriasis. CD123 positivity and transepidermal elimination of elastin have recently been reported as tools to distinguish HLE. Interestingly, in this case, biopsies of two separate lesions failed to reveal these two features. The etiology of this discrepancy is unknown and further studies are needed to clarify the utility of CD123 positivity and transepidermal elimination of elastin in the diagnosis of hypertrophic lupus erythematosus.
Report of case
A 49-year-old, unemployed, white male presented with a three-year history of an expanding "rash". He reported no constitutional symptoms. He had previously been treated with oral prednisone and an unknown topical steroid without improvement and was off all medications at our initial visit. The patient had a past medical history of hepatitis C. He denied a family history of skin or autoimmune diseases. Laboratory work-up was significant for positive anti-nuclear antibodies and anti-Ro antibodies. Physical exam revealed multiple hyperkeratotic, verrucous papules and nodules with white, scaly, cribriform centers overlying patches of depigmentation, erythema and atrophy on his bilateral arms ( Figure 1 ) and anterior legs. His face and scalp had several atrophic, depigmented patches. Two punch biopsies were obtained from separate lesions. Histological sections demonstrated an interface inflammatory pattern with deep peri-vascular and peri-appendageal lymphocytic infiltrate and rare plasma cells (Figure 2 ). A diagnosis of HLE was made. The patient was prescribed clobetasol ointment 0.05% twice daily. At the three month follow-up, there was improvement of the hypertrophic lesions. The patient was subsequently lost to follow-up.
Discussion
HLE was first described by Bechet in 1940 3 . Clinical diagnosis can be challenging as HLE can mimic psoriasis or even squamous In this patient, we examined these two recently described histologic features of HLE. Interestingly, both CD123 positivity and transepidermal elimination of elastin were not present in this case. However, the histological and clinical findings were most consistent with HLE. The etiology of this discrepancy is unknown and further studies are needed to clarify the utility of CD123 positivity and transepidermal elimination of elastin in the diagnosis of hypertrophic lupus erythematosus.
There is no definitive treatment for HLE. Options include topical or intralesional steroids, topical or oral retinoids, topical calcineurin inhibitors, thalidomide, hydroxychloroquine and surgical excision 5, 6 . Winchester et al. reported on the efficacy TNF-alpha inhibitors 7 .
This case highlights the discrepancies of CD 123 positivity and transepidermal elimination of elastin in HLE.
Consent
Written informed consent for publication of clinical details and clinical images was obtained from the patient.
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Victoria P. Werth
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA This is a case of hypertrophic lupus erythematosus that is described as unusual in pathologic presentation.
The title needs to indicate absence of transepidermal elimination of elastin. It is currently unclear if transepidermal elmination of elastin was present.
The order of treatment described for HLE is confusing. One would start with hydroxychloroquine, then add quinacrine to hydroxychloroquine, with topicals as adjunctive therapy. Oral retinoids, thalidomide, and immuosuppressives would be options. Given that frequently there are multiple lesions that may actually koebnerize in a surgical scar, one would not include surgical excision as an option.
The report cited in favor of TNF-alpha inhibitor is on ustekinumab, which is not a TNF inhibitor. This needs revision.
Information about the antibody used for CD123 staining, as well as whether frozen or fixed tissue was used, is important. Anti-CD123 staining is not as good on fixed tissue. Were there any positive controls stained simultaneously?
No competing interests were disclosed.
Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Reader Comment 28 May 2014
, UAMS, USA Jerad Gardner Thank you for your commentary. The title has been changed to more clearly reflect the absence of transepidermal elimination in this case. The treatments listed in the report were a review of treatment options from the literature. They were not ordered as a suggested line of therapy. Ustekinumab has been reported to improve the plaques of hypertrophic lupus erythematosus. It is an inhibitor of IL-12 and IL-23. This fact has been corrected. We performed CD 123 staining on paraffin embedded tissue which is the method employed in her report on the novel use of Ko et al. CD 123 staining in hypertrophic lupus erythematosus. The second version of this report will contain a figure displaying positive control staining and negative CD 123 staining of the biopsy from this case.
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